Bayer AG (OTC:BAYRY) on Tuesday proposed a $7.25 billion settlement to resolve thousands of U.S. lawsuits claiming that its weedkiller Roundup causes cancer. The product was originally made by Monsanto, which Bayer acquired in 2018 for more than $60 billion. “Litigation uncertainty has plagued the company for years, and this settlement gives the company a road to closure,” said Bayer CEO Bill Anderson. If approved by the court, the settlement would reduce potential exposure stemming from a future Supreme C ...

US President Donald Trump speaks during a Black History Month event in the East Room of the White House in Washington, DC, on Feb. 18, 2026."I find that ensuring robust domestic elemental phosphorus mining and United States-based production of glyphosate-based herbicides is central to American economic and national security," Trump said in the order. "Without immediate Federal action, the United States remains inadequately equipped and vulnerable."Glyphosate is often targeted by supporters of the Make Ameri ...

Group 1 - Bayer's Monsanto unit has proposed a U.S. class settlement of up to $7.25 billion to resolve claims that Roundup weedkiller caused Non-Hodgkins lymphoma [1][2] - The proposed settlement aims to cover the majority of pending cases in U.S. state and federal courts and will require judicial approval [2] - Bayer is preparing additional settlements for existing U.S. Roundup cases valued at approximately $3 billion [2] Group 2 - The settlement proposal includes a provision for individuals diagnosed with Non-Hodgkins lymphoma who were exposed to Roundup to file claims for up to 21 years [3] - Bayer expects its provisions and litigation liabilities to increase from €7.8 billion to €11.8 billion, with anticipated litigation-related payouts of around €5 billion in 2026 [3] - The company has postponed the publication of its 2025 results and 2026 guidance to March 4 to reflect these agreements [4]

Bayer (OTCPK:BAYR.Y) Update / briefing February 17, 2026 12:30 PM ET Company ParticipantsAnja Ettel - News reporterBill Anderson - CEOBill Dodero - Head of Litigation and North America LegalCharles Pitman-King - VPDietrich Knauth - Media RepresentativeJost Reinhard - Head of Investor RelationsSonja Wind - News ReporterWolfgang Nickl - CFOConference Call ParticipantsAlec Ebeling - Equity Research AnalystBert Günther - Equity Research AnalystLaurent Favre - Equity Research AnalystRajesh Kumar - Equity Researc ...

Core Viewpoint - The U.S. Supreme Court will review the Durnell Roundup™ case, which is significant for Monsanto as it addresses the split in authority among federal circuit courts regarding federal preemption in Roundup™ litigation [1] Summary by Relevant Categories Legal Developments - Monsanto petitioned the Supreme Court to hear the Durnell case in April 2025, with an expected decision on the merits during the Court's 2026 session, which concludes in June [1] Industry Impact - The Supreme Court's decision to take the case is viewed positively for U.S. farmers, indicating potential implications for the agricultural sector and the use of Roundup™ products [1]

Core Viewpoint - Bayer's Monsanto has initiated a lawsuit against COVID-19 vaccine manufacturers Pfizer, BioNTech, and Moderna, claiming they have improperly utilized its messenger RNA technology in the production of their vaccines [1] Group 1: Legal Action - The lawsuit was filed in Delaware federal court, indicating a formal legal challenge to the vaccine makers [1] - The core allegation revolves around the alleged misuse of messenger RNA technology, which is critical in the development of mRNA vaccines [1] Group 2: Implications for the Industry - This legal action could have significant implications for the biotechnology and pharmaceutical sectors, particularly regarding intellectual property rights and technology usage in vaccine development [1] - The outcome of this lawsuit may influence future collaborations and innovations within the mRNA technology space [1]

RT Peter St Onge, Ph.D. (@profstonge)RFK: Monsanto created Celiac DiseaseBtw, here's a chart of glyphosate on wheat (i.e. Roundup) and celiac disease hospital discharges: https://t.co/cY5fqRTh0m ...

I'm starting with Warner Brothers. This guy. Okay, w bd their shares have been up nearly 2%, so it's feeling the second round of bids right from Netflix.Paramount Skydance's Comcast that includes a mostly cash offer from Netflix. Paramount's offer reportedly includes debt financing from Apollo. Sources are saying Middle East funds also contributing to that.But you had bankers from Paramount, you know Netflix, they were all busy over Thanksgiving. You know, the long weekend sources saying an auction could wr ...

Core Viewpoint - The U.S. Solicitor General supports Bayer's request for the Supreme Court to review rulings regarding the health impacts of Roundup, potentially affecting the company's liability in ongoing lawsuits [1][7]. Bayer's Stock Performance - Shares of Bayer surged 12% on the German exchange following the Solicitor General's support for the Supreme Court review [1]. Regulatory Background - The Environmental Protection Agency has stated that glyphosate, a key ingredient in Roundup, is "not likely to be carcinogenic in humans," and the Food and Drug Administration has approved numerous labels for Roundup without cancer warnings [2][7]. Legal Arguments - Bayer contends that since federal agencies deem glyphosate safe, customers should not be able to sue under state laws for failing to warn about cancer risks. Most of the ongoing lawsuits are based on "failure-to-warn theories," which could be invalidated by a favorable Supreme Court ruling for Bayer [3][4]. Implications for Investors - A Supreme Court ruling in favor of Bayer could prevent the company from paying billions in settlements related to cancer risk allegations, while a ruling against it could benefit thousands of cancer patients and their families [4]. Bayer's Strategy - Bayer welcomes the Solicitor General's support, stating that a Supreme Court ruling would clarify the company's obligations under state laws versus federal determinations of chemical safety. The company aims to significantly reduce litigation by the end of 2026 [5]. Acquisition Context - Bayer acquired Monsanto in 2018 for $63 billion, and shortly after the acquisition, a California jury found Monsanto liable for failing to warn about Roundup's potential cancer risks [5].

Bayer AG agreed to settle fresh cases related to a Seattle-area school and people’s exposure to toxic chemicals at the facility made by the company’s Monsanto unit https://t.co/KYt5O63Q8R ...